MRI可疑区超声特征可预测融合靶向活检中临床显著前列腺癌
该前瞻性队列纳入1058例接受MRI-超声融合靶向活检的男性,由术者对MRI感兴趣区(ROI)的超声表现分级为0、1、2级。672例分析显示,超声分级越高,任何前列腺癌和Gleason评分≥7癌的检出率均显著升高,且超声分级是Gleason评分≥7癌的独立预测因素。
要点
- MRI ROI处超声低回声区分级越高,前列腺癌检出率越高。
- 超声分级可独立预测Gleason评分≥7前列腺癌。
- 融合靶向活检时识别ROI超声特征有助于风险分层。
核心结论
- MRI感兴趣区部位的超声表现可独立预测Gleason评分≥7前列腺癌的可能性,边界清晰的低回声区者风险更高。
研究设计与样本
- 前瞻性纳入2011年7月至2017年6月由单一术者行MRI-超声融合靶向活检(联合或不联合系统活检)的1058例男性,最终672例纳入分析。
- 由单一放射科医生对每个MRI ROI进行可疑评分,术者前瞻性评估ROI处超声低回声区并分级为0、1、2级(无、边界不清、边界清晰)。
主要发现
- 672例男性总体前列腺癌检出率为61.2%,Gleason评分≥7癌检出率为39.6%。
- 超声分级0、1、2级的任何前列腺癌检出率分别为46.2%、58.6%、76.0%(P < 0.001)。
- 超声分级0、1、2级的Gleason评分≥7癌检出率分别为18.7%、35.2%、61.1%(P < 0.001)。
- 仅行MRI-超声融合靶向活检时,超声分级0、1、2级的Gleason评分≥7癌检出率分别为12.8%、25.7%、52.0%(P < 0.001)。
- 多因素回归显示超声分级、前列腺特异性抗原密度和MRI可疑评分可预测靶向活检中Gleason评分≥7前列腺癌。
关键数值与推荐
- 超声分级0、1、2级分别代表无低回声区、边界不清的低回声区、边界清晰的低回声区。
- 在MRI可疑评分2-4分的男性中,单因素分析显示超声分级可预测Gleason评分≥7癌检出率。
临床怎么用
- 行MRI-超声融合靶向活检时,应关注MRI ROI处是否存在超声低回声区及其边界清晰度,以辅助判断临床显著前列腺癌风险。
局限性
- 单术者操作,超声评估可能存在主观性。
- 部分患者联合系统活检,可能影响检出率归因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether the presence of an ultrasound hypoechoic region at the site of a region of interest (ROI) on magnetic resonance imaging (MRI) results in improved prostate cancer (PCa) detection and predicts clinically significant PCa on MRI-ultrasonography fusion-targeted prostate biopsy (MRF-TB). MATERIALS AND METHODS: Between July 2011 and June 2017, 1058 men who underwent MRF-TB, with or without systematic biopsy, by a single surgeon were prospectively entered into an institutional review board-approved database. Each MRI ROI was identified and scored for suspicion by a single radiologist, and was prospectively evaluated for presence of a hypoechoic region at the site by the surgeon and graded as 0, 1 or 2, representing none, a poorly demarcated ROI-HyR, or a well demarcated ROI-HyR, respectively. The interaction of MRI suspicion score (mSS) and ultrasonography grade (USG), and the prediction of cancer detection rate by USG, were evaluated through univariate and multivariate analysis. RESULTS: For 672 men, the overall and Gleason score (GS) ≥7 cancer detection rates were 61.2% and 39.6%, respectively. The cancer detection rates for USGs 0, 1 and 2 were 46.2%, 58.6% and 76.0% (P < 0.001) for any cancer, and 18.7%, 35.2% and 61.1% (P < 0.001) for GS ≥7 cancer, respectively. For MRF-TB only, the GS ≥7 cancer detection rates for USG 0, 1 and 2 were 12.8%, 25.7% and 52.0%, respectively (P < 0.001). On univariate analysis, in men with mSS 2-4, USG was predictive of GS ≥7 cancer detection rate. Multivariable regression analysis showed that USG, prostate-specific antigen density and mSS were predictive of GS ≥7 PCa on MRF-TB. CONCLUSIONS: Ultrasonography findings at the site of an MRI ROI independently predict the likelihood of GS ≥7 PCa, as men with a well-demarcated ROI-HyR at the time of MRF-TB have a higher risk than men without.
引用
- Press B, Rosenkrantz AB, Huang R, et al. The ultrasound characteristics of regions identified as suspicious by magnetic resonance imaging (MRI) predict the likelihood of clinically significant cancer on MRI-ultrasound fusion-targeted biopsy. BJU Int. 2018. PMID: 30415476. doi:10.1111/bju.14615
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。